NCCN 2017 Nursing Program Webinar Series - Clinical Updates and Issues: Colorectal Cancer

June 27, 2017

The 2017 NCCN Nursing Program: Advancing Oncology Nursing Live Webinar Series will provide oncology nurses with comprehensive and clinically relevant information to optimize patient education and care. Information is focused on current and critical issues to provide oncology nurses with practical information that can be implemented in the practice setting.

Target Audience

This activity is designed to meet the educational needs of oncology nurses who manage patients with cancer.

Additional information
Supporters: 

This activity is supported by educational grants from Gilead Sciences, Medical Affairs; Pfizer and Taiho Oncology. This activity is supported by educational funding provided by Amgen. This activity is supported by independent educational grants from AbbVie; Incyte; and Merck Co., Inc.

Course summary
Available credit: 
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
06/26/2017
Course expires: 
08/27/2017
Event starts: 
06/27/2017 - 1:00pm
Event ends: 
06/27/2017 - 2:00pm
Cost:
$0.00

Cyndy Simonson, MS, APRN-BC, AOCN
Duke Cancer Institute

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below discloses the following relevant financial relationships:
Cyndy Simonson, MS, APRN-BC, AOCN
AstraZeneca Pharmaceuticals LP: Scientific Advisor
Bayer HealthCare: Product/Speakers Bureau
Celgene Corporation: Product/Speakers Bureau
Genentech, Inc.: Product/Speakers Bureau
Sandoz Inc.: Scientific Advisor
Taiho Parmaceuticals Co., Ltd.: Product/Speakers Bureau

The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kimberly Bayer; Robert W. Carlson, MD; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Kimbro, MBA, CPA; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN (employed by NCCN until 2/7/17); Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser (employed by NCCN until 2/3/17); Gary J. Weyhmuller, MBA, SPHR

The NCCN Clinical Information staff listed below, who has reviewed content, discloses no relevant financial relationships:
Mary Anne Bergman; Mary Dwyer, MS; Ellen Erkess Uskuraitis; Deborah Freedman-Cass, PhD; Lisa Gurski, PhD; Miranda Hughes, PhD; Rashmi Kumar, PhD; Jillian Scavone, PhD; Hema Sundar, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

Nurses
National Comprehensive Cancer Network is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Available Credit

  • 1.00 ANCC contact hours
  • 1.00 Participation

Learning Objectives

Following this activity, participants should be able to:

  • Evaluate the potential clinical utility of PD-1 immune checkpoint inhibitors in patients with metastatic colorectal cancer
  • Summarize the most common side effects of PD-1 immune check point inhibitors
  • Implement strategies for the prevention and management of treatment-related toxicities

Accreditation Period

Course opens: 
06/26/2017
Course expires: 
08/27/2017

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Reader or other PDF reader software for certificate viewing/printing